CTI BioPharma Corp. (CTIC) Financial Statements (2026 and earlier)

Company Profile

Business Address 3101 WESTERN AVENUE
SEATTLE, WA 98121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:79,93965,44652,50033,70067,00027,218
Cash and cash equivalent30,42065,44640,39431,14436,43927,218
Short-term investments49,519 12,0572,52230,599 
Other undisclosed cash, cash equivalents, and short-term investments   4934(38) 
Restricted cash and investments      16,000
Receivables15,387    4
Inventory, net of allowances, customer advances and progress billings733    550
Inventory733    550
Other undisclosed current assets3,3372,9331,8251,88015,4923,152
Total current assets:99,39668,37954,32535,58082,49246,924
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization  1767191,2351,7932,365
Intangible asset, including goodwill, after accumulated amortization23,226     
Intangible asset, excluding goodwill, after accumulated amortization23,226     
Other noncurrent assets3,3033,8793,1979,4655,5475,597
Total noncurrent assets:26,5294,0553,91610,7007,3407,962
TOTAL ASSETS:125,92572,43458,24146,28089,83254,886
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31,41016,6118,82811,60617,35016,478
Accounts payable2,0083,8911,637 4,4982,588
Accrued liabilities29,40212,7207,19111,60612,85213,890
Debt47,94347,3804,4554,8124,812444
Other liabilities1,7812,6603,7552,0708931,424
Deferred revenue and credits✕✕✕✕✕✕912
Total current liabilities:81,13466,65117,03818,48823,05519,258
Noncurrent Liabilities
Long-term debt and lease obligation    4,4559,26713,575
Long-term debt, excluding current maturities    4,4559,26713,575
Liabilities, other than long-term debt2,4682,0161,1745,4074,5715,963
Deferred revenue and credits✕✕✕✕✕✕494
Other liabilities1,2342,0161,1745,4074,5715,469
Operating lease, liability 1,234   ✕✕
Other undisclosed noncurrent liabilities59,900     
Total noncurrent liabilities:62,3682,0161,1749,86213,83819,538
Total liabilities:143,50268,66718,21228,35036,89338,796
Equity
Equity, attributable to parent, including:(17,577)3,76740,02923,68858,69421,813
Preferred stock      1,090
Common stock131100765858 
Additional paid in capital2,501,2342,429,5822,367,9582,299,1862,294,025 
Accumulated other comprehensive income (loss)(35) 2(11,993)(10,643)(6,272)
Accumulated deficit(2,518,907)(2,425,915)(2,328,007)(2,263,563)(2,224,746)(2,195,346)
Other undisclosed equity, attributable to parent      2,222,341
Equity, attributable to noncontrolling interest    (5,758)(5,755)(5,723)
Total equity:(17,577)3,76740,02917,93052,93916,090
TOTAL LIABILITIES AND EQUITY:125,92572,43458,24146,28089,83254,886

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues53,9481,254 3,34526,29025,146
Revenue, net✕✕✕✕✕✕25,146
Sublease income 4151,254  ✕✕
Cost of revenue(3,514)  (786)(4,574)(364)
Cost of product and service sold     (879)(364)
Gross profit:50,4341,254 2,55921,71624,782
Operating expenses(121,721)(95,332)(47,769)(43,270)(54,615)(64,301)
Other operating income (expense), net(8,510)     
Other undisclosed operating loss  (1,254)    
Operating loss:(79,797)(95,332)(47,769)(40,711)(32,899)(39,519)
Nonoperating income (expense)(13,195)(2,576)(4,682)6883,547(1,312)
Investment income, nonoperating   (3,570)1,1721,219 
Gain (loss), foreign currency transaction, before tax  (80)(281)(233)817
Other nonoperating income (expense)(56)(161) 1,3204,295(94)
Interest and debt expense(13,139)(2,415)(511)(1,002)(1,209)(163)
Loss from continuing operations:(106,131)(100,323)(52,962)(41,025)(30,561)(40,994)
Loss before gain (loss) on sale of properties:✕(100,323)(52,962)(41,025)(30,561)(40,994)
Other undisclosed net income13,139 5111,0021,209163
Net loss:(92,992)(100,323)(52,451)(40,023)(29,352)(40,831)
Net income attributable to noncontrolling interest    332161
Other undisclosed net income attributable to parent  2,415    
Net loss attributable to parent:(92,992)(97,908)(52,451)(40,020)(29,320)(40,670)
Preferred stock dividends and other adjustments     (80)(4,350)
Net loss available to common stockholders, diluted:(92,992)(97,908)(52,451)(40,020)(29,400)(45,020)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(92,992)(100,323)(52,451)(40,023)(29,352)(40,831)
Other comprehensive income (loss)(35)(2)2(1,350)(4,371)383
Other undisclosed comprehensive income  2,415    
Comprehensive loss:(93,027)(97,910)(52,449)(41,373)(33,723)(40,448)
Comprehensive income, net of tax, attributable to noncontrolling interest    332161
Comprehensive loss, net of tax, attributable to parent:(93,027)(97,910)(52,449)(41,370)(33,691)(40,287)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: